ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, announced the close of a $1 million seed round led by company co-founder Michael Torres, Ph.D., following his role as Co-Founder and Chief Executive Officer of CrossBridge Bio through its acquisition by Eli Lilly. The financing will support advancement of ARTAN Bio's proprietary mutation-specific codon suppression platform toward first-in-human development.

In conjunction with the financing, ARTAN Bio also announced the appointment of Brian Bodemann as Chief Executive Officer. Bodemann brings a research-grade command of the science together with broad exposure across life-science commercial markets - positioning him to bridge ARTAN Bio's platform with the indications and partners it can ultimately serve. Co-founder Anthony Schwartz, Ph.D., will transition from Chief Executive Officer to Chief Operating Officer, strengthening the company's operational and scientific leadership as it advances the platform through the next stage of translational development.